Funding sources This work was supported by Bristol-Myers Squibb. Representatives from Bristol-Myers Squibb were involved in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication and have been listed as authors of this manuscript. Editorial and writing assistance was provided by StemScientific, funded by Bristol-Myers Squibb. None of the authors received financial compensation for authoring the manuscript.
Clinical and Laboratory Investigations
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study
Article first published online: 13 JAN 2014
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 1, pages 87–95, January 2014
How to Cite
Lorigan, P., Marples, M., Harries, M., Wagstaff, J., Dalgleish, A.G., Osborne, R., Maraveyas, A., Nicholson, S., Davidson, N., Wang, Q., Pericleous, L., Bapat, U. and Middleton, M.R. (2014), Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. British Journal of Dermatology, 170: 87–95. doi: 10.1111/bjd.12503
Conflicts of interest P.L. has acted as a consultant/advisor to Bristol-Myers Squibb, Roche, Novartis, Celgene and GSK, and has also received travel support from Bristol-Myers Squibb and Roche. M.M. has received travel support from and acted as a consultant/advisor to Bristol-Myers Squibb. R.O. has acted as a consultant/advisor to Bristol-Myers Squibb. At the time of writing, U.B. and Q.W. were employees of Bristol-Myers Squibb. Q.W. is currently at GlaxoSmithKline, Stockley Park, Uxbridge, U.K. L. P. is currently at Novo Nordisk, Copenhagen, Denmark.
- Issue published online: 13 JAN 2014
- Article first published online: 13 JAN 2014
- Accepted manuscript online: 16 JUL 2013 03:04AM EST
- Manuscript Accepted: 1 JUL 2013
- Bristol-Myers Squibb
Advanced melanoma is an aggressive disease with a poor prognosis. Approved therapy is limited in the U.K. and, until recently, no treatment had improved survival over best supportive care. A deeper understanding of current clinical practice will help new agents find a place in future treatment pathways.
To document U.K. clinical practice for the treatment of patients with unresectable stage III/IV (advanced) melanoma.
MELODY (melanoma treatment patterns and outcomes among patients with unresectable stage III/IV disease: a retrospective longitudinal survey) compiled registries of consecutive patients with malignant melanoma (any stage) between 1 July 2005 and 30 June 2006 from France, Italy and the U.K. Patients with advanced melanoma and ≥ 2 months of follow-up were eligible for analysis.
There were 220 eligible patients identified in the U.K., of whom 117 (53·2%) received systemic therapy outside of clinical trials. Over half of these patients received dacarbazine as first- or second-line therapy. Healthcare-resource utilization was extensive and patients had short survival times: 1- and 2-year survival rates after first-line systemic treatment were 45·5% [95% confidence interval (CI) 37·1–53·6] and 24·7% (95% CI 17·7–32·3), respectively.
Systemic and palliative treatments used to manage advanced melanoma in the U.K. are associated with considerable healthcare resource utilization and poor short-term survival.